Research shows that nearly 50% of people with HIV now live with obesity, and that lifestyle changes, GLP-1 medicines, and weight-loss surgery may all help manage it. According to research reviewed by Gram, diet and activity remain the first-line approach, while larger trials are still needed to confirm long-term benefits.
Many people living with HIV struggle with weight gain, a side effect linked to some modern HIV medicines. According to research reviewed by Gram, nearly half of people with HIV now live with obesity, which can raise the risk of heart, kidney, and metabolic problems. This 2026 Series paper in The Lancet HIV pulls together the current evidence on managing weight in this group. It highlights three main options: diet and physical activity changes, including eating more protein and moving more regularly; GLP-1 medicines, which have growing but still limited study in people with HIV; and bariatric (weight-loss) surgery, which appears safe and effective for many. The authors also point out major gaps, such as few large clinical trials and little information on how treatments may affect men and women differently. Researchers say more high-quality studies are urgently needed before clear, specific treatment guidelines can be written.
Key Statistics
A 2026 review published in The Lancet HIV found that nearly 50% of people with HIV are living with obesity, a rate linked in part to guideline-recommended antiretroviral therapy.
A 2026 Lancet HIV Series paper reported that weight gain and obesity worsen cardiovascular, kidney, and metabolic health complications in people with HIV, and that chronic weight management is now an urgent priority.
The Quick Take
- What they studied: How can doctors and patients manage excess weight in people living with HIV, and what does the current evidence say about each option?
- Who participated: This is a review paper rather than a single experiment, so it did not enroll new participants. It summarizes earlier studies that included adults living with HIV who had weight gain or obesity.
- Key finding: Nearly 50% of people with HIV are living with obesity, a rate that appears to be driven in part by certain HIV medicines. The paper finds that lifestyle changes, GLP-1 medicines, and weight-loss surgery each show promise, but the evidence for many treatments in this group is still thin.
- What it means for you: If you live with HIV and are concerned about weight gain, talk with your HIV care team about options. Diet and activity changes are a common first step, while medicines and surgery should be discussed with a doctor who knows your full health history.
The Research Details
This article is a Series paper, a type of review that gathers and explains what is known about a health topic. The authors looked at existing research on weight gain and obesity in people with HIV, focusing on diet, physical activity, medicines, and surgery. Instead of running a new experiment, they examined the findings of earlier studies and judged how strong that evidence is.
The paper covers several treatment approaches. Behavioral programs aim to improve eating habits and increase physical activity, with an emphasis on getting enough protein and moving regularly. The authors also review the growing number of studies on GLP-1 medicines, which help control appetite and blood sugar, and a older body of research on a drug called tesamorelin, which was studied mainly for reducing fat around the abdomen.
Finally, the authors review studies on bariatric surgery, a procedure that changes the digestive system to help with weight loss. They also identify where research is missing, which helps set priorities for future studies.
A review like this is useful because it brings scattered findings together into one picture. Individual studies in people with HIV are often small, so looking at the whole body of evidence helps show which treatments have a consistent track record and which are still unproven.
The paper also highlights what is not yet known. By pointing out gaps, such as the lack of large trials on heart outcomes and the limited data on sex differences, it guides researchers toward the questions that most need answers. This helps clinicians and patients understand that some recommendations are based on strong data while others are still educated guesses.
This paper appears in The Lancet HIV, a well-known medical journal, and it is written by specialists in HIV and obesity care. Series papers are typically reviewed by expert editors, which adds credibility.
Readers should keep in mind that a review reflects the authors’ judgment about existing studies. It does not test anything new, and it does not list a specific number of participants. Its conclusions are only as strong as the research it summarizes, and the authors themselves note that many key trials have not yet been done.
What the Results Show
The paper reports that excess weight gain is now recognized as a common concern for people taking guideline-recommended HIV treatment (antiretroviral therapy). Nearly half of people with HIV are living with obesity, and this matters because weight gain and obesity can worsen problems with the heart, kidneys, and metabolism.
For lifestyle changes, the authors say behavioral programs can help people improve their diet and become more active. Increasing protein intake and building regular physical activity are highlighted as practical strategies. These approaches are widely recommended for the general population, and the authors suggest they can be adapted for people with HIV.
For medicines, the paper notes growing evidence supporting GLP-1 receptor agonist therapies in people with HIV. It also mentions earlier research showing tesamorelin works in this group, though its focus is different. The authors note that data on other approved obesity medicines in people with HIV are sparse, so their use should be guided carefully.
For surgery, the authors suggest that bariatric procedures appear to be both safe and effective for people with chronic HIV and obesity. However, they also note that this evidence base is limited and that more studies are needed to confirm these results over time.
The authors point out that the research community lacks trials of GLP-1 medicines in people with HIV that are large enough to measure serious outcomes, such as major heart events or changes in body composition. Without these trials, it is hard to know how much these medicines reduce long-term risk in this group.
The paper also calls for implementation science, a field that studies how to put proven care into everyday practice. Researchers need to determine which models of care work best in busy HIV clinics, including who delivers weight management support and how it is paid for.
Finally, the authors highlight the need to study whether weight-loss outcomes differ between men and women. Understanding these differences could help doctors tailor treatment more precisely.
The paper builds on a growing recognition that certain HIV medicines are linked to weight gain, which has shifted attention from simply controlling the virus to also protecting long-term health. It also fits with broader obesity research showing that diet, activity, medicines, and surgery can all help, while noting that people with HIV have often been left out of major obesity trials.
The review’s emphasis on tesamorelin and GLP-1 therapies reflects how the field has developed. Earlier work on tesamorelin focused on body fat distribution, while newer GLP-1 research has expanded the conversation toward heart and kidney health.
The main limitation is that this is a review, not a new study. Its conclusions depend on the quality of the earlier studies it draws from, and many of those studies were small or short in length.
The authors themselves acknowledge that evidence is sparse for several treatments, especially newer obesity medicines in people with HIV. The paper also does not provide a single set of numbers, such as overall weight loss averages, that would allow readers to compare options directly.
Another limitation is that the review cannot show exactly how much each approach will help any one person, since individual results vary based on health history, medicines, and other factors.
The Bottom Line
Lifestyle support, including protein-focused eating and regular physical activity, is a reasonable first step for people with HIV who have weight gain. Confidence in this approach is moderate, since it is widely supported in general populations and the authors describe it as a practical starting point.
GLP-1 medicines show growing promise in people with HIV, but confidence is still developing because large trials on heart and body composition outcomes are not yet complete. Weight-loss surgery appears safe and effective for selected patients, though confidence is limited by the small amount of long-term data.
No single treatment can be recommended as the best choice for everyone. Decisions should be individualized with an HIV care provider.
People living with HIV who have gained weight or have obesity should pay close attention, especially if they also have heart, kidney, or blood sugar concerns. Healthcare providers who care for people with HIV will find the review useful for understanding current options and research gaps.
People without HIV are not the direct audience for these findings, although the general principles of diet and activity overlap with broader health advice. Anyone considering medicines or surgery should not make changes without consulting a doctor.
Lifestyle changes often take several weeks to months before weight or energy levels shift noticeably, and results vary widely between people. Medicines such as GLP-1 drugs usually show effects over a few months, but their long-term benefits on heart and kidney health are still being studied.
Bariatric surgery results typically appear over the first one to two years after the procedure, though long-term outcomes in people with HIV are still being documented. Patients should expect gradual progress and plan for ongoing follow-up.
Frequently Asked Questions
How common is obesity in people living with HIV?
According to a 2026 review in The Lancet HIV, nearly 50% of people with HIV are living with obesity. Weight gain is linked in part to guideline-recommended HIV treatment, which is why researchers call weight management an urgent priority.
Can diet and exercise help with weight gain from HIV medicines?
Behavioral interventions that improve diet and increase physical activity are recommended for people with HIV. Increasing protein intake and building regular exercise are highlighted as practical strategies, though the review notes that more studies are needed to measure long-term results.
Are GLP-1 medicines safe and effective for people with HIV?
Growing evidence supports GLP-1 receptor agonist therapies in people with HIV. However, the review notes that large trials measuring major heart events and body composition are still lacking, so long-term benefits remain under study.
Is weight-loss surgery an option for people with HIV and obesity?
Bariatric surgery appears to be safe and effective for people with chronic HIV infection and obesity, according to a 2026 Lancet HIV review. Decisions should be made with an HIV care team, since long-term data in this group are still limited.
Want to Apply This Research?
- Track daily protein intake in grams and weekly minutes of moderate physical activity. Recording body weight once a week, at the same time of day, can also show trends more clearly than daily fluctuations.
- Add a source of protein, such as eggs, beans, fish, poultry, tofu, or Greek yogurt, to each meal. Set a weekly goal of at least 150 minutes of moderate activity, like brisk walking, and break it into short sessions if needed.
- Review your logs monthly to spot patterns in weight, protein intake, and activity. Share summaries with your HIV care team at routine visits so they can adjust your plan and check for any changes in heart, kidney, or blood sugar markers.
This article summarizes a review paper for general information only and is not medical advice. Weight management plans, medicine decisions, and surgery choices for people living with HIV should be made with a qualified healthcare provider who knows your full medical history, including your current HIV treatment.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.